Alphamab Oncology (Stock Code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. ("CSPC") (Stock Code: 1093.HK) jointly announced that anti-HER2 biparatopic antibody-drug conjugate (ADC) JSKN003 has ...

The PATHWAY HER2 (4B5) test is now FDA-approved to assess HER2-ultralow status in metastatic breast cancer, expanding its ...

The FDA has approved a companion diagnostic to determine if patients with HR-positive, HER2-ultralow metastatic breast cancer are eligible for T-DXd treatment.

The researchers found that imlunestrant prolonged progression-free survival (PFS) when compared to standard care in patients with ESR1 mutations, but there was no PFS benefit observed in the overall ...

Novartis UK announced the Medicines and Healthcare products Regulatory Agency (MHRA) has authorised ribociclib for adjuvant ...

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on February 4, 2025, the Compensation ...

New England Journal of Medicine Publishes eNRGy Trial Evaluating Zenocutuzumab-zbco (BIZENGRI®) in NRG1+ cancer ...

Novartis’ Kisqali (ribociclib) has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) to treat a ...

这些研究发现支持了RAD51测试在调整早期乳腺癌患者疗法策略上的潜力，未来的生物标志物的驱动研究（比如RADIOLA研究）就旨在验证RAD51在晚期乳腺癌中的作用，其结果预计将会在今年晚些时候公布，而研究人员应该考虑利用目前的数据来完善分层因素并改善 ...

Antibody Drug Conjugates Market Market Growth Fueled by Advancements in ADC Technology, Increased Demand for Targeted Cancer Therapies, and ...

Study finds that ultrafast MRI-based radiomics model performs just as well as standard MRI in classifying breast cancer ...

The international consulting firm Clarivate makes its bet among the novelties ready for the medicine cabinet this year: three ...